首页> 外文期刊>Diabetes >Discrete and Complementary Mechanisms of Protection of β-Cells Against Cytokine-Induced and Oxidative Damage Achieved by bcl-2 Overexpression and a Cytokine Selection Strategy
【24h】

Discrete and Complementary Mechanisms of Protection of β-Cells Against Cytokine-Induced and Oxidative Damage Achieved by bcl-2 Overexpression and a Cytokine Selection Strategy

机译:bcl-2过表达实现β细胞抗细胞因子诱导的氧化性损伤的离散和互补机制及细胞因子选择策略

获取原文
获取原文并翻译 | 示例
       

摘要

We have been investigating the potential utility of engineered cell lines as surrogates for primary islet cells in treatment of type 1 diabetes. To this end, two strategies that have emerged for procuring cell lines with resistance to immune-mediated damage are 1) selection of cytokine-resistant cell lines by growth of INS-1 insulinoma cells in iteratively increasing concentrations of interleukin (IL)-1β + γ-interferon (IFN-γ), and 2) stable overexpression of the anti-apoptotic gene bcl-2 in INS-1 cells. Herein, we show that bcl-2―overex-pressing cells are resistant to the cytotoxic effects of reactive oxygen and nitrogen species (ROS/RNS), but are only modestly protected against high concentrations of IL-1β + INF-γ, whereas the converse is true in cytokine selected cells. We also found that the combination of bcl-2 expression and cytokine selection confers a broader spectrum of resistance than either procedure alone, such that the resultant cells are highly resistant to cytokines and ROS/RNS, with no impairment in glucose-stimulated insulin secretion. INS-1―derived cells with combined bcl-2 expression and cytokine selection are also more resistant to damage induced by coculture with mitogen-activated peripheral blood mononuclear cells. Surprisingly, application of the cytokine selection procedure to bcl-2―overexpressing cells does not result in impairment of nuclear factor-κB translocation, iNOS expression, and NO production, as clearly occurs upon application of the selection procedure to cells without bcl-2 overexpression. Further investigation of the diverse pathways involved in the development of cytokine and ROS/RNS resistance may define simplified and specific strategies for preservation of β-cell mass.
机译:我们一直在研究工程细胞系作为替代胰岛细胞治疗1型糖尿病的潜在用途。为此,用于获得对免疫介导的损伤具有抵抗力的细胞系的两种策略是:1)通过以不断增加的白介素(IL)-1β+浓度增加INS-1胰岛素瘤细胞的生长来选择抗细胞因子的细胞系。 γ-干扰素(IFN-γ)和2)在INS-1细胞中稳定表达抗凋亡基因bcl-2。在这里,我们表明bcl-2过表达细胞对活性氧和活性氮(ROS / RNS)的细胞毒性作用具有抗性,但仅适度保护其免受高浓度IL-1β+INF-γ的侵害,而在细胞因子选择的细胞中则相反。我们还发现,bcl-2表达和细胞因子选择的组合比单独使用任何一种方法都具有更广的抗药性,从而使所得细胞对细胞因子和ROS / RNS具有高度抗性,并且在葡萄糖刺激的胰岛素分泌方面没有任何损害。结合了bcl-2表达和细胞因子选择的INS-1衍生细胞也对有丝分裂原激活的外周血单核细胞共培养引起的损伤更有抵抗力。出乎意料的是,将细胞因子选择程序应用于过表达bcl-2的细胞不会导致核因子-κB易位,iNOS表达和NO生成受到损害,这显然适用于将选择程序应用于没有bcl-2过表达的细胞。进一步研究涉及细胞因子和ROS / RNS耐药性发展的多种途径,可能会为保存β细胞团块定义简化和特定的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号